Portfolio Lab

Tg Therapeutics, Inc.

  • Stock
  • Ticker TGTX
  • ISIN US88322Q1085
  • Nasdaq

Health care · Pharmaceuticals · USA

$63.34 −2.37%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Tg Therapeutics, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

TGTXGlobal equities (VT)

$10,000 grew to $104,694. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −93.2% in 06/2022, measured from the peak in 12/2020. It took 66 months to get back to the old peak.

1-year return
+108.0%
5-year return p.a.
+21.0%
10-year return p.a.
+26.5%
Volatility p.a.
87.2%
Largest decline
−93.2%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue108121141162193205240260
Gross profit93105122134154171199218
Operating income308.6352950352286
EBITDA308.6352951352286
Net income235.12839123207.855
Earnings per share0.150.030.172.430.150.120.050.35
Balance sheet
Total assets5786577031,0251,0631,5291,6401,592
Liabilities3554194264184159461,0361,020
Equity222237276607648583604572
Cash1801321297479442483429
Long-term debt244245245245246745745746
Cash flow
Operating cash flow-26-297.4-2320-183945
Capital expenditure0.00.00.0-0.1-0.1-0.1-0.3-0.3
Free cash flow-26-297.4-2320-183945

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +368.6%, weakest 2021 at −63.5%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
9 Nov 2026$0.35
5 Aug 2026$0.05
6 May 2026$0.12
27 Feb 2026$0.15
5 Nov 2025$2.43
8 Aug 2025$0.17
9 May 2025$0.03
3 Mar 2025$0.15
7 Nov 2024$0.02
9 Aug 2024$0.04
6 May 2024−$0.07
29 Feb 2024−$0.10

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€8.7bn
Market cap in trading currency
$9.57bn
Enterprise value
$9.81bn
P/E
94.5
P/S
10.66
P/B
16.73
EV/Sales
10.93
EV/EBITDA
50.8
Earnings yield
1.1%
FCF yield
0.9%

Results (last four quarters)

Revenue
$898m
Gross profit
$743m
EBITDA
$193m
Net income
$106m
Earnings per share
$0.67
Revenue per share
$5.94
Revenue growth
+60.7%
Earnings growth
−85.8%

Profitability

Gross margin
82.7%
Operating margin
21.5%
Net margin
11.8%
Return on equity
18.0%
Return on assets
6.7%

Balance sheet and cash flow

Cash
$505m
Cash per share
$3.34
Financial debt
$746m
Debt/equity %
130
Current ratio
4.50
Book value per share
$3.79
Operating cash flow
$86.3m
Free cash flow
$85.6m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
151m
Volume
2.08m
Avg. volume 3 months
1.91m
Relative volume
1.1

Price and technicals

Price
$63.34
1 day
−2.4%
52-week high
$66.12
52-week low
$26.94
Distance to 52-week high
−4.2%
Distance to 52-week low
+135.1%
Distance to 50-day line
+10.0%
Distance to 200-day line
+36.9%
RSI (14)
57
Volatility 1M
46.9%

Performance

1 week
−1.8%
1 month
+19.1%
3 months
+13.1%
6 months
+63.0%
YTD
+112.5%
1 year
+108.8%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has TGTX performed since 11/2016?

$10,000 grew to $104,694 by 20 Nov 2026, which is +26.5% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is TGTX?

Volatility was 87.2% per year, measured on monthly returns. The largest decline from a peak was −93.2%, with the low in 06/2022.

How does TGTX compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, TGTX returned +26.5% at 87.2%. The correlation of monthly returns was 0.37; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Tg Therapeutics, Inc. (TGTX): Return and risk